Characterizing and understanding body weight patterns in patients treated with pregabalin

References

• Ness-Abramof R, Apovian CM. Drug-induced weight gain. Drugs Today (Barc) 2005;41:547-55
   PubMed Web of Science ®Google Scholar
• Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-78
   PubMed Web of Science ®Google Scholar
• Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 2010;68:277-81
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity and Overweight 2006 September 2006 [cited 2011 23 Sept ]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/index.html
   Google Scholar
• Pfizer Inc. LYRICA prescribing information. Section 5.7 Weight Gain. 2004 [cited 9th March, 2012]. Available from: http://www.pfizer.com/files/products/uspi_lyrica.pdf
   Google Scholar
• Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805
   PubMed Web of Science ®Google Scholar
• Arroyo S, Anhut H, Kugler AR, et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45:20-7
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-31
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63
   PubMed Web of Science ®Google Scholar
• Lee BI, Yi S, Hong SB, et al. Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial. Epilepsia 2009;50:464-74
   PubMed Web of Science ®Google Scholar
• Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone 2009;9:55-68
   PubMedGoogle Scholar
• Frame B, Beal SL, Miller R, et al. Mixed effects modeling of weight change associated with placebo and pregabalin administration. J Pharmacokinet Pharmacodyn 2007;34:753-70
   PubMed Web of Science ®Google Scholar
• Miller R, Beal SL, Frame B, et al. Modeling of weight change associated with pregabalin and placebo administration. Eur J Neurol 2006;13:113 [abstract]
   Web of Science ®Google Scholar
• Jandhyala VK, Zacks S, El-Shaarawi AH. Change-point methods and their applications: contributions of Ian MacNeill. Environmetrics 1999;10:657-76
   Web of Science ®Google Scholar
• MacNeill IB, Mao Y. Change-point analysis for mortality and morbidity rate. In: Sinha BK, Rukhin AL, Ahsanullah M, eds. Applied Change Point Problems in Statistics. Nova Science Publishers, 1995:172
   Google Scholar
• French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med 2008;359:166-76
   PubMed Web of Science ®Google Scholar
• Hoppe C, Rademacher M, Hoffmann JM, et al. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure 2008;17:327-32
   PubMed Web of Science ®Google Scholar
• Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-50
   PubMed Web of Science ®Google Scholar
• Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006;70:467-76
   PubMed Web of Science ®Google Scholar
• Wittmann G, Lechan RM, Liposits Z, et al. Glutamatergic innervation of corticotropin-releasing hormone- and thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Brain Res 2005;1039:53-62
   PubMed Web of Science ®Google Scholar
• Rivest S, Deshaies Y, Richard D. Effects of corticotropin-releasing factor on energy balance in rats are sex dependent. Am J Physiol 1989;257:R1417-22
   PubMed Web of Science ®Google Scholar
• Karolyi IJ, Burrows HL, Ramesh TM, et al. Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad Sci U S A 1999;96:11595-600
   PubMed Web of Science ®Google Scholar
• Gaspari CN, Guerreiro CA. Modification in body weight associated with antiepileptic drugs. Arq Neuropsiquiatr 2010;68:277-81
   PubMed Web of Science ®Google Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448-54
   PubMed Web of Science ®Google Scholar
• Yanovski JA, Yanovski SZ, Sovik KN, et al. A prospective study of holiday weight gain. N Engl J Med 2000;342:861-7
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96
   PubMed Web of Science ®Google Scholar